Autolus Therapeutics (AUTL) Research & Development (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Research & Development for 9 consecutive years, with $35.6 million the latest figure, recorded in Q4 2025.

• Quarterly Research & Development rose 15.58% year-over-year to $35.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $117.7 million (down 14.99% YoY) and the FY2025 annual result came in at $117.7 million, down 14.99% from the prior year.
• Research & Development grew to $35.6 million in Q4 2025 per AUTL's latest filing, from $27.9 million in the prior quarter.
• Over the last five years, Research & Development for AUTL reached as high as $40.3 million in Q3 2024 and fell as low as $7.5 million in Q4 2022.
• A 5-year average of $29.8 million and a median of $30.8 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2021 — Research & Development tumbled 59.5% — and 2023, when it surged 397.39%.
• Year by year, Research & Development stood at $15.7 million in 2021, then plunged by 51.88% to $7.5 million in 2022, then jumped by 397.39% to $37.5 million in 2023, then slipped by 17.88% to $30.8 million in 2024, then gained by 15.58% to $35.6 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $35.6 million, $27.9 million, and $27.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.